Document Detail


Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention?
MedLine Citation:
PMID:  18307738     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
1. The measurement of plasma levels of B-type natriuretic peptide (BNP) and amino-terminal pro-BNP (NT-proBNP) provides useful diagnostic information in patients with suspected heart failure and valuable prognostic information in patients with heart failure, acute coronary syndrome, valvular heart disease and other cardiac pathologies. 2. BNP- and NT-proBNP-guided heart failure therapy improves patient outcomes. 3. An increasing number of studies shows plasma BNP and NT-proBNP levels predict all-cause mortality and cardiovascular events including heart failure, myocardial infarction, stroke, atrial fibrillation and cardiovascular death in stable patients with or without known cardiovascular disease and provide information about cardiovascular risk additional to that provided by traditional risk factors. 4. Antihypertensive therapy reduces elevated NT-proBNP levels in individuals at increased cardiovascular risk, thereby suggesting that change in NT-proBNP levels provides a measure of risk reduction. 5. Thus, monitoring of BNP and NT-proBNP levels offers the possibilities of improved targeting of individuals with increased cardiovascular risk and optimization of strategies for primary and secondary prevention of cardiovascular disease. 6. There is need for an outcome study to determine whether BNP- or NT-proBNP-guided therapy improves cardiovascular disease prevention.
Authors:
Duncan J Campbell
Related Documents :
15861008 - Novel markers for heart failure diagnosis and prognosis.
19033018 - Independent prognostic value of echocardiography and n-terminal pro-b-type natriuretic ...
19346228 - C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with hea...
20825928 - Cardiac ultrasound helps for differentiating the causes of acute dyspnea with available...
6762808 - Usefulness of multiaxis echocardiography in assessment of the left ventricle in ischemi...
17556168 - Severe coronary artery calcifications are associated with ischemia in patients undergoi...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical and experimental pharmacology & physiology     Volume:  35     ISSN:  1440-1681     ISO Abbreviation:  Clin. Exp. Pharmacol. Physiol.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-02-29     Completed Date:  2008-05-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0425076     Medline TA:  Clin Exp Pharmacol Physiol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  442-6     Citation Subset:  IM    
Affiliation:
St Vincent's Institute of Medical Research and the Department of Medicine, University of Melbourne, St Vincent's Hospital, Fitzroy, Victoria, Australia. dcampbell@svi.edu.autoria
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular Diseases / blood*,  prevention & control*
Humans
Natriuretic Peptide, Brain / blood*
Peptide Fragments / blood*
Risk Factors
Chemical
Reg. No./Substance:
0/Peptide Fragments; 0/pro-brain natriuretic peptide (1-76); 114471-18-0/Natriuretic Peptide, Brain

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Promoting physiological hypertrophy in the failing heart.
Next Document:  Control of sympathetic, respiratory and somatomotor outflow by an intraspinal pattern generator.